Aktuellt
SENASTE
We have taken a sceptical view regarding the potential threat from Sparsentan (Travere Therapeutics) ahead of additional long-term data from more extensive studies regardless of an early (premature) approval or not. Hence we are not highlighting the impact of the recent delayed Sparsentan PDUFA date.
LÄS MER
